Loading…
Employees: 128
Size PharmaNutra (PHN.MI) is an Italy Health Care company (Pharmaceuticals: Other) with a market value of $808M, the 91st largest of 123 Italy companies the cockpit tracks. Shares closed at €74.40 on 6 Nov 2026.
Performance Over six months the shares fell 17.8%, against -16.5% for the median peer and +3.1% for the Italy market (cap-weighted) — 10th lowest of 21 in its peer set.
Growth Revenue grew 17.7% over the last twelve months (peer median -4.2%); the operating margin is 21.2% (peer median 6.8%).
Valuation It trades at 29.6× forward earnings against a peer median of 24.2× (6th most expensive of 12).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 23.8 points above its cost of capital (6.3% WACC).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €143M | €132M | €115M | €100M | €82.7M |
| Revenue growth | — | +14% | +15% | +21% | — |
| Gross profit | €94.7M | €88.9M | €78.2M | €61.2M | €54.6M |
| EBITDA | €33.8M | €32.3M | €30.2M | €24.9M | €23.8M |
| Net income | €20.7M | €20.0M | €16.6M | €12.8M | €15.0M |
| Free cash flow | €15.7M | €16.4M | €16.2M | -€1.16M | -€8.69M |
| Capital expenditure | €3.36M | €3.13M | €4.19M | €13.2M | €23.2M |
| Total debt | €18.4M | €20.5M | €24.3M | €28.0M | €17.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PHN.MI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.7% | -8.4% | 4th highest of 21 |
| 6-month return | -17.8% | -16.5% | 10th lowest of 21 |
| Distance from 52-week high | -22.4% | -37.7% | 3rd highest of 21 |
| Revenue growth (TTM) | +17.7% | -4.2% | 5th highest of 20 |
| Operating margin | 21.2% | 6.8% | 5th highest of 19 |
| Forward P/E | 29.6× | 24.2× | 6th most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | 4.0% | 4.9% | 6th least demanding of 12 |
| Growth delivered (Del g) | +18.5% | +12.1% | 2nd highest of 12 |
| Hurdle (Req g minus delivered) | -14.5 pp | -3.0 pp | 3rd least demanding of 12 |
| ROIC minus cost of capital | +23.8 pp | -0.2 pp | 4th highest of 19 |
| EV / EBITDA | 21.4× | 17.5× | 3rd cheapest of 5 |
| Net debt / EBITDA | 0.1× | -2.8× | 2nd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PharmaNutra PHN.MI | Italy | $808M | -18% | +18% | 21% | 29.6× | 4.0% | +18.5% |
| Tianjin Tianyao Pharmaceuticals 600488.SS | China | $801M | -14% | -12% | 3% | n/a | 3.6% | -1.3% |
| Sirio Pharma 300791.SZ | China | $790M | -12% | -9% | 1% | 16.9× | 14.7% | +15.6% |
| Shanghai Kaibao Pharmaceutical 300039.SZ | China | $756M | -17% | -14% | 22% | n/a | 1.8% | +4.8% |
| China Shineway Pharmaceutical 2877.HK | Hong Kong | $719M | -21% | -18% | 25% | 7.2× | n/a | n/a |
| TSI 603262.SS | China | $909M | -41% | +3% | 14% | 51.5× | 25.8% | +13.4% |
| Brother Enterprises 002562.SZ | China | $716M | -28% | +8% | 4% | n/a | 4.9% | +13.5% |
| Shanxi Zhendong Pharmaceutical 300158.SZ | China | $713M | -16% | -28% | -25% | n/a | n/a | n/a |
| Sihuan Pharmaceutical 0460.HK | Hong Kong | $952M | -35% | +30% | 15% | 9.7× | n/a | n/a |
| ArriVent BioPharma AVBP | United States | $673M | -54% | n/a | n/a | n/a | n/a | n/a |
| New Journey Health Technology Group Co., Ltd.Class A 002219.SZ | China | $999M | -16% | -14% | 8% | 193.0× | n/a | n/a |
| Applied Nutrition APN.L | United Kingdom | $1.01B | +42% | +24% | n/a | 24.2× | n/a | n/a |
| CK Life Sciences International (Holdings) 0775.HK | Hong Kong | $644M | -30% | 0% | 0% | n/a | n/a | n/a |
| ABA Chemicals 300261.SZ | China | $641M | -27% | -16% | -23% | 438.0× | n/a | n/a |
| Hangzhou Minsheng Healthcare 301507.SZ | China | $624M | -21% | +21% | 11% | 48.6× | 20.4% | +12.1% |
| Shandong Xinhua Pharmaceutical 000756.SZ | China | $1.09B | -10% | -5% | 4% | 18.3× | 1.5% | +7.9% |
| Lanzhou Foci Pharmaceutical 002644.SZ | China | $582M | -9% | +3% | 5% | n/a | 24.3% | +6.5% |
| Hunan Hansen Pharmaceutical 002412.SZ | China | $582M | +10% | -4% | 21% | n/a | 3.0% | +7.0% |
| Lionco Pharmaceutical 603669.SS | China | $581M | +21% | -6% | -17% | n/a | n/a | n/a |
| HBM 2142.HK | Hong Kong | $1.18B | -23% | +55% | 44% | 12.4× | 14.1% | +62.3% |
| BioGaia BIOG-B.ST | Sweden | $1.26B | -7% | +13% | 28% | 30.1× | 0.9% | +15.5% |